India Pharma Outlook Team | Thursday, 24 September 2026
European regulators open a new chapter for young asthma patients by extending single-inhaler triple therapy access to teenagers.
AstraZeneca’s Trixeo Aerosphere now reaches patients aged 12 and older whose asthma stays poorly controlled on dual therapy.
This fixed-dose combination of budesonide, glycopyrronium and formoterol fumarate packs three proven agents into one device.
Doctors gain a practical tool that targets both airway inflammation and muscle constriction.
Families facing daily wheezing, breathlessness and the constant threat of flare-ups receive clearer hope for steadier control.
The decision builds on strong trial evidence and marks Trixeo as the first and only triple-combination option available in the EU for this age group, regardless of prior exacerbation history.
The European Commission approved Trixeo Aerosphere as daily maintenance treatment for asthma patients 12 years of age and older. Doctors prescribe it when medium-dose inhaled corticosteroid plus long-acting beta2-agonist therapy fails to keep symptoms in check.
The single inhaler delivers the traditional ICS/LABA pairing together with a long-acting muscarinic antagonist, simplifying what once required multiple devices.
Key facts about the medicine include:
AstraZeneca grounded the approval in positive results from the KALOS and LOGOS Phase III trials. These studies enrolled roughly 4,300 patients and compared Trixeo against combined ICS/LABA treatments.
Trixeo delivered statistically significant gains in lung function. A pooled analysis further showed a clear reduction in the annualized rate of severe asthma exacerbations across a broad population, including people who had experienced no exacerbations in the previous year.
Trial highlights stand out:
Results appeared in The Lancet Respiratory Medicine in February 2026, giving clinicians solid peer-reviewed data.
Also Read: Why Vaccine Innovation Must Go Beyond Traditional Platforms
Alberto Papi, Professor and Chair of Respiratory Medicine at the University of Ferrara and primary investigator, sees the daily reality of uncontrolled asthma. He notes that many patients still struggle with persistent symptoms and declining lung function despite standard dual therapy.
The new single-inhaler triple option improves control and lowers future exacerbation risk for patients from age 12 upward. Ruud Dobber, Executive Vice President and President of AstraZeneca’s BioPharmaceuticals Business Unit, emphasizes the broader impact.
The approval extends Trixeo’s proven benefits from COPD into the asthma setting, bringing single-inhaler triple therapy to European patients aged 12 and older whose asthma remains uncontrolled on dual inhaled treatment.
Nearly 43 million people live with asthma in Europe, and about four million more receive a new diagnosis each year. Roughly half of those on dual therapies continue to experience uncontrolled disease.
Symptoms such as wheezing, breathlessness, coughing, and exacerbations can escalate and, in severe cases, prove life-threatening conditions. Trixeo offers a streamlined way to address both inflammation and bronchoconstriction in one daily step.
The same triple combination already holds asthma approvals in the United States and Japan and remains under review in China and other markets. It also carries COPD indications in more than 90 countries worldwide.
This extension of single-inhaler triple therapy to teens and adults alike gives clinicians a practical, evidence-backed choice. Patients who previously needed multiple inhalers or faced ongoing symptoms now have access to a simpler regimen designed to improve daily lung function and cut the risk of serious flare-ups.
.jpg)
